8-K: Cencora Acquires OneOncology Majority Stake for $5B

Cencora announced it will acquire the majority of OneOncology for approximately $5.0 billion, accelerating its specialty solutions offering and raising long-term guidance.

Summary

• Cencora, Inc. has agreed to acquire the majority of outstanding equity interests in OneOncology, a physician-led national oncology platform.
• The total cash consideration for the acquisition is approximately $5.0 billion, comprising $3.6 billion for equity interests and $1.3 billion to retire OneOncology's existing corporate debt.
• OneOncology's enterprise value is $7.4 billion, with an equity value of approximately $6 billion.
• The transaction is expected to be funded through new debt financing, with $4.5 billion in bridge financing commitments secured.
• OneOncology's affiliated practices and management will retain a minority interest.
• The acquisition is anticipated to close by the end of Cencora's fiscal 2026 second quarter, subject to customary closing conditions and regulatory approvals.
• The acquisition is expected to be approximately neutral to Cencora's adjusted diluted EPS in the first twelve months post-close, net of financing costs.
• Cencora is reiterating its fiscal 2026 consolidated guidance, with adjusted diluted EPS likely towards the lower half of the $17.45 to $17.75 range due to a pause in share repurchases.
• Long-term guidance for adjusted operating income (7% to 10%) and adjusted diluted EPS (10% to 14%) has been raised to reflect OneOncology's expected long-term contribution.

Sentiment

Score: 7

Explanation: The acquisition is a significant strategic move that enhances Cencora's specialty solutions and raises long-term growth expectations. While there's a short-term neutral EPS impact and paused share repurchases, the overall strategic direction and long-term outlook are positive, indicating confidence in future growth.

Positives

• Accelerates Cencora's acquisition of OneOncology, strengthening its management services organization and pharmaceutical-centric strategy.
• Enhances Cencora's solutions in specialty care, supporting physicians and pharmaceutical innovators.
• Leverages OneOncology's strong network and physician-led approach to attract leading practices.
• Improves patient access to pharmaceuticals, simplifying cancer care navigation, speeding clinical trial enrollment, and driving access to novel treatments.
• Raises long-term guidance for adjusted operating income (7% to 10%) and adjusted diluted EPS (10% to 14%).
• Cencora remains committed to maintaining its strong investment grade credit ratings.

Negatives

• The acquisition is expected to be approximately neutral to adjusted diluted EPS in the first twelve months following close, net of financing costs.
• Cencora is pausing share repurchases, which will likely push fiscal 2026 adjusted diluted EPS towards the lower half of its guidance range ($17.45 to $17.75).
• The transaction will be funded through new debt financing, increasing the company's leverage in the short term.

Risks

• Failure to achieve expected or targeted future financial and operating performance and results.
• Inability to achieve expected benefits, synergies, and operating efficiencies from the transaction within expected time frames or at all.
• Business disruption being greater than expected following the transaction.
• Difficulty in recruiting and retaining key physicians and employees after the transaction.
• Impact of changes in customer and supplier relationships and customer purchasing patterns.
• Impacts of competition.
• Changes in the economic and financial conditions of Cencora or OneOncology.
• Inability to maintain Cencora's investment grade rating due to de-leveraging plans.
• Uncertainties and matters beyond the control of management.

Future Outlook

Cencora expects the OneOncology acquisition to be approximately neutral to adjusted diluted EPS in the first twelve months post-close. The company has raised its long-term guidance for adjusted operating income (7% to 10%) and adjusted diluted EPS (10% to 14%) to reflect OneOncology's expected long-term contribution. Fiscal 2026 adjusted diluted EPS is anticipated to be towards the lower half of the $17.45 to $17.75 range due to a pause in share repurchases.

Management Comments

• "We are excited to accelerate our acquisition of OneOncology, which will advance our management services organization and aligns with our approach of making growth-oriented investments that support our pharmaceutical-centric strategy." Bob Mauch, President & CEO of Cencora.
• "Since our initial investment in OneOncology, the platform has grown substantially as its physician-led approach continues to attract leading practices and physicians, supporting patient access to high-quality care in local communities." Bob Mauch, President & CEO of Cencora.
• "We are pleased to advance our longstanding partnership with Cencora, who shares our commitment to supporting independent providers, while still maintaining our independence, will allow us to enhance the value we provide to practices, improving physicians ability to focus on delivering accessible and innovative care to their patients." Jeff Patton, M.D., CEO of OneOncology.

Industry Context

The acquisition strengthens Cencora's position in the specialty pharmaceutical solutions market, particularly in oncology. It aligns with a trend of healthcare providers seeking partners to streamline operations, support advanced treatments, and enhance patient access to innovative therapies in complex care areas like cancer. The focus on a physician-led platform and community-based care reflects a strategy to maintain quality and access outside of large hospital systems.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through enhanced strategic positioning and raised long-term guidance, but short-term EPS neutrality and paused share repurchases may temper immediate returns.
• Employees: OneOncology's affiliated practices and management will retain a minority interest, suggesting continuity and integration rather than immediate disruption.
• Customers (Care Providers): Cencora aims to provide enhanced tools to streamline operations, support cutting-edge treatments, and enable more patient engagement through OneOncology's MSO and clinical support solutions.
• Patients: Expected to benefit from enhanced access to pharmaceuticals, simplified cancer care navigation, speedier clinical trial enrollment, and access to novel treatments in a cost-effective setting.
• Creditors: New debt financing will be incurred, but Cencora is committed to maintaining investment grade ratings and prioritizing deleveraging.

Next Steps

• Satisfy customary closing conditions, including receipt of required regulatory approvals.
• Close the transaction by the end of Cencora's fiscal 2026 second quarter.
• Incorporate the impact of the OneOncology acquisition into Cencora's fiscal 2026 guidance expectations following the transaction close.
• Prioritize deleveraging following the transaction to maintain investment grade credit ratings.

Key Dates

Recommendation

The acquisition of OneOncology is a significant strategic move that strengthens Cencora's core pharmaceutical-centric strategy by expanding its specialty solutions in oncology. The raised long-term guidance for both adjusted operating income and adjusted diluted EPS indicates management's confidence in the accretive nature of this deal over time. While the short-term EPS impact is neutral and share repurchases are paused, these are temporary considerations for a long-term growth-oriented investment. The focus on maintaining an investment-grade rating and deleveraging post-transaction also provides financial stability. This acquisition positions Cencora for sustained growth in a critical healthcare segment.

Keywords

Cencora, OneOncology, Acquisition, Oncology, Healthcare Solutions, Pharmaceuticals, Specialty Care, Debt Financing, EPS Guidance, Strategic Investment, Medical Specialty Practices, TPG